About: A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 10 April 2012

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2012 (fr) наукова стаття, опублікована у квітні 2012 (uk) scientific article published on 10 April 2012 (en) 2012 թվականի ապրիլի 10-ին հրատարակված գիտական հոդված (hy) artículu científicu espublizáu n'abril de 2012 (ast)
publication date	wds:Q83875007-28DE081A-423D-4D12-87EB-35A7EA6BBEED
publication date	2012-04-10 00:00:00Z (xsd:dateTime)
author name string	wds:Q83875007-33AD64FA-023B-435F-9631-73C7E439EF0B wds:Q83875007-8A5394CE-920D-47A2-87B0-2F43FF83418C wds:Q83875007-954C0324-7EFD-48C8-A359-0B0D9E839BBE wds:Q83875007-9C58C08E-513D-4F00-8893-D7626D6C38BE wds:Q83875007-AA1F293D-BC5F-4EAE-AB39-744DE8A450C0
author name string	Antonio Anzueto James F Donohue Rashmi Mehta Jean Brooks Christopher Kalberg
rdfs:label	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (en) A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (nl)
skos:prefLabel	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (en) A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (nl)
name	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (en) A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (nl)
author	wds:Q83875007-30F27BDA-8B60-4A5B-A706-3AF0128D1856
author	Glenn Crater
title	wds:Q83875007-A5A8A18D-E081-4965-9252-6CF2B8DD5A9E
title	A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD (en)
page(s)	wds:Q83875007-150A5F50-711A-49C7-8E9D-D99F97CD7295
page(s)	970-979
instance of	wds:Q83875007-D31ABEC7-3E59-4F04-9F4A-C8F5B7AFA927
instance of	scholarly article
PubMed ID	wds:Q83875007-1106C28D-0BF3-4D50-8A5F-7A09BF8C2E9E
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22498110
PubMed ID	22498110
published in	wds:Q83875007-513F142E-7C1B-4531-8114-D376DA4A7708
published in	Respiratory Medicine
issue	wds:Q83875007-8992DF0B-1A3D-47D6-911F-A164EB85EC9A
volume	wds:Q83875007-27A734CE-D403-4BCA-8740-5B512023A3BA
issue	7
volume	106
DOI	wds:Q83875007-CE49EE62-7768-4A8C-A585-BB6F978BA619
DOI	http://dx.doi.org/10.1016/J.RMED.2012.03.012
DOI	10.1016/J.RMED.2012.03.012
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q83875007
is cites work of	Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA Umeclidinium bromide and vilanterol trifenatate inhalation powder Safety, tolerability and pharmacokinetics and pharmacodynamics of inhaled once-daily umeclidinium in healthy adults deficient in CYP2D6 activity: a double-blind, randomized clinical trial. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trial Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers Determination of the pharmacokinetics of glycopyrronium in the lung using a population pharmacokinetic modelling approach A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD Pharmacokinetics and tolerability of inhaled umeclidinium and vilanterol alone and in combination in healthy Chinese subjects: a randomized, open-label, crossover trial A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD. Inhaled Umeclidinium in COPD Patients: A Review and Meta-Analysis Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study Patient considerations in the treatment of COPD: focus on the new combination inhaler umeclidinium/vilanterol Dose-response modelling of umeclidinium and fluticasone furoate/umeclidinium in asthma Effect of severe renal impairment on umeclidinium and umeclidinium/vilanterol pharmacokinetics and safety: a single-blind, nonrandomized study Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic? Efficacy and Safety of Once-Daily Inhaled Umeclidinium in Asian Patients with COPD: Results from a Randomized, Placebo-Controlled Study Inhaled treatment for chronic obstructive pulmonary disease: what's new and how does it fit? Evidence-based review of data on the combination inhaler umeclidinium/vilanterol in patients with COPD Emergency Hospital Care for Exacerbation of COPD: Is Inhaled Maintenance Therapy Modified?
is cites work of	wds:Q26752988-51D53F96-8394-4217-826B-7C60434EEE23 wds:Q33774769-22E40B27-13FC-4F6C-AFB1-0901ED5B3CF0 wds:Q36388517-6D9F607C-FB7A-4642-84B6-C77A82C31D7C wds:Q42858000-83AD4740-BBC0-4449-8218-1B2D71733E19 wds:Q38717900-35E0F631-2BDD-43A7-9C18-E559C801FC2F wds:Q39297047-2BFC5382-0FC4-48ED-A491-D603A24F271A wds:Q24561751-F6B5C47D-ACB4-48F3-BDAB-027D806C6E95 wds:Q40737609-25B0AE64-5200-4B11-8323-FA721146E3E8 wds:Q34787196-8AE17A26-42F3-4B36-8DB1-37CF1CD9A22C wds:Q38352425-F0D5BCFA-2A5C-41A6-8B6D-B0A271B6557A wds:Q94525576-394CB299-7D8D-4828-A35A-3328EEB586E6 wds:Q38630770-C9F691E6-174F-451B-94A4-D289C214BFE6 wds:Q47946666-A4934639-F9AC-46AF-A7F6-08DBD87F3824 wds:Q35224900-C0FDC255-F1BA-4208-B05B-BB2A94E792EE wds:Q38692883-A59F8A39-BA25-415A-A577-FDEF4A813F18 wds:Q48293345-E1D37412-5FCF-4D88-9CC8-C48D819B1696 wds:Q93025924-D4EF30D0-DCAB-4CDB-AE4D-053A59C00C49 wds:Q28596637-3A35A9C5-C7B3-4CE8-B79F-BAFC123BCF16 wds:Q33643220-607422BB-9BAE-4A0F-8B8D-D815EE47C25C wds:Q37533170-6E799105-CCC8-4408-9504-35BFC883539A wds:Q38154255-6921D7D1-89F7-45CC-9571-FB8AF8195B46 wds:Q26777927-7492E403-AD30-4AE7-8A2F-A42D86DC43F6 wds:Q36787818-D44C7B7B-4608-4C23-AE1B-6DA0DD9126A9 wds:Q36652471-93CBA4BE-B504-4C19-A7F2-B5F428D36366 wds:Q40449015-5D179D27-7D7F-4D67-AF6B-A88AFDBE111C wds:Q36738741-018E82DB-3190-47FB-8924-C1EBB4F50516

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 190 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software